A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer
MUI SINGEL, Stina, CORNELIUS, Crystal, BATTEN, Kimberly, FASCIANI, Gail, WRIGHT, Woodring E, LUM, Lawrence, SHAY, Jerry W
Published in Clinical cancer research (15.04.2013)
Published in Clinical cancer research (15.04.2013)
Get full text
Journal Article
IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors
Starodub, Alexander, Gabrail, Nashat Y., Zhang, Ying, Torrejon Castro, Davis Y, Slavsky, Sibel, Singel, Stina Mui, Powderly, John D.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation
Starodub, Alexander, Powderly, John D., Kim, Sung-Bae, Davar, Diwakar, Hill, Andrew Graham, Yeku, Oladapo O., Gabrail, Nashat Y., Krapp, Christian, Pihl, Susanne, Zhang, Ying, Slavsky, Sibel, Torrejon Castro, Davis Y, Uyei, Anne, Singel, Stina Mui, Kwatra, Vineet
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
TransCon IL-2 β/γ, a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 analog, demonstrates improved pharmacokinetics and profound expansion of cytotoxic immune cells in non-human primates
Rosen, David, Månsson Kvarnhammar, Anne, Olling, Janne Damm, Laufer, Burkhardt, Knappe, Thomas, Karlsson, Jens Jakob, Kurpiers, Thomas, Zettler, Joachim, Runz, Josefine, Faltinger, Frank, Viet, Laura, Krusch, Mathias, Schnabel, Meike, Reich, Diana, Glock, Philipp, Singel, Stina Mui, Sprogøe, Kennett, Abel, Kristin Laura, Breinholt, Vibeke Miller, Punnonen, Juha
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC)
Tannir, Nizar M., Agarwal, Neeraj, Pal, Sumanta K., Cho, Daniel C., Formiga, Maria, Guo, Jun, George, Daniel J., Tagliaferri, Mary Ann, Singel, Stina Mui, O'Keeffe, Bridget A., Hannah, Alison L., Balbas, Minna, Penkov, Konstantin
Published in Journal of clinical oncology (20.02.2020)
Published in Journal of clinical oncology (20.02.2020)
Get full text
Journal Article
LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC)
Kim, Sung-Bae, Tan, Antoinette R., Im, Seock-Ah, Villanueva, Rafael, Valero, Vicente, Saura, Cristina, Oliveira, Mafalda, Isakoff, Steven J., Singel, Stina Mui, Dent, Rebecca Alexandra
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer
Isakoff, Steven J., Saura, Cristina, Calvo, Isabel, Gil Gil, Miguel J., Patt, Debra A., Morales Murillo, Serafin, Andersen, Jay C., Ciruelos, EVA, Fisher, Julie Gottlieb, Passos-Coelho, Jose, de La Pena, Lorena, Kapp, Amy V., Gendreau, Steven, Chan, Wai Y., Singel, Stina Mui, Maslyar, Daniel J., Baselga, Jose, Oliveira, Mafalda
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC)
Oliveira, Mafalda, Saura, Cristina, Gonzalez-Martin, Antonio, Andersen, Jay C., Fisher, Julie Gottlieb, Calvo, Isabel, Ciruelos, Eva, Gil, Miquel, De La Pena, Lorena, Llobet-Canela, Marta, Choi, YounJeong, Jia, Shidong, Yalamanchili, Sreenivasu, Singel, Stina Mui, Patel, Premal H., Baselga, Jose, Isakoff, Steven J.
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article